Table 4 Summary of tumor response according to ESR1 mutational status
Wildtype ESR1 N = 20 | Mutated ESR1 N = 9 | Biomarker positive, mutated ESR1 N = 7 | |
|---|---|---|---|
Best overall response — n (%) | |||
Complete response | 0 | 0 | 0 |
Partial response | 4(20.0) | 3(33.3) | 3(42.9) |
Stable disease (≥6 weeks) | 11(55.0) | 6(66.7) | 4(57.1) |
Progressive disease | 5(25.0) | 0 | 0 |
Non-evaluable | 0 | 0 | 0 |
Objective response rate (90% CI) | 20.0(7.1–40.1) | 33.3(9.8–65.5) | 42.9(12.9–77.5) |
Clinical benefit rate (90% CI) | 70.0(49.2–86.0) | 77.8(45.0–95.9) | 85.7(47.9–99.3) |
Median (95% CI) duration of response, months | 19.1 (3.7-NA) | 4.5 (3.8-NA) | 4.5 (3.8-NA) |
Median (95% CI) progression-free survival, months | 7.3 (3.6-NA) | 8.2 (5.6-NA) | 8.2 (5.6-NA) |
